Who are Cosopt PF 2%-0.5% Ophthalmic Solution's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cosopt-pf-2-0-5-ophthalmic-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Cosopt PF 2%-0.5% Ophthalmic Solution — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cosopt PF 2%-0.5% Ophthalmic Solution (Cosopt PF 2%-0.5% Ophthalmic Solution) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fixed-dose combination of carbonic anhydrase inhibitor and beta-blocker. Area: Ophthalmology.

marketed Fixed-dose combination of carbonic anhydrase inhibitor and beta-blocker Carbonic anhydrase II (dorzolamide component); beta-adrenergic receptors (timolol component) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Cosopt PF 2%-0.5% Ophthalmic Solution (Cosopt PF 2%-0.5% Ophthalmic Solution) — Prairie Eye Center. Cosopt PF combines a topical carbonic anhydrase inhibitor (dorzolamide) and a beta-blocker (timolol) to reduce intraocular pressure through decreased aqueous humor production.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cosopt PF 2%-0.5% Ophthalmic Solution TARGET	Cosopt PF 2%-0.5% Ophthalmic Solution	Prairie Eye Center	marketed	Fixed-dose combination of carbonic anhydrase inhibitor and beta-blocker	Carbonic anhydrase II (dorzolamide component); beta-adrenergic receptors (timolol component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fixed-dose combination of carbonic anhydrase inhibitor and beta-blocker class)

Prairie Eye Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cosopt PF 2%-0.5% Ophthalmic Solution — Competitive Intelligence Brief. https://druglandscape.com/ci/cosopt-pf-2-0-5-ophthalmic-solution. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab